Sight Sciences, Inc. (SGHT)

US — Healthcare Sector
Peers: RXST  AXGN  TMCI  LUNG  OFIX  RPID  CTKB  EVCM 

Automate Your Wheel Strategy on SGHT

With Tiblio's Option Bot, you can configure your own wheel strategy including SGHT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SGHT
  • Rev/Share 1.4724
  • Book/Share 1.351
  • PB 2.5462
  • Debt/Equity 0.5795
  • CurrentRatio 10.0059
  • ROIC -0.4428

 

  • MktCap 180143715.0
  • FreeCF/Share -0.4323
  • PFCF -8.0403
  • PE -3.6376
  • Debt/Assets 0.3326
  • DivYield 0
  • ROE -0.5938

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 2
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade SGHT Lake Street Hold Buy -- $5 Aug. 8, 2025
Initiation SGHT UBS -- Buy -- $5.5 Dec. 6, 2024
Initiation SGHT Lake Street -- Buy -- $10 Aug. 21, 2024

News

Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use
SGHT
Published: September 17, 2025 by: GlobeNewsWire
Sentiment: Neutral

MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the results as published in the European Journal of Ophthalmology of a systematic review and meta-analysis of the clinical effectiveness, safety, humanistic and economic impact of the OMNI Surgical System (OMNI).

Read More
image for news Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use
Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease
SGHT
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral

Cost-Utility Analysis published in the Expert Review of Pharmacoeconomics and Outcomes Research Cost-Utility Analysis published in the Expert Review of Pharmacoeconomics and Outcomes Research

Read More
image for news Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease

About Sight Sciences, Inc. (SGHT)

  • IPO Date 2021-07-15
  • Website https://www.sightsciences.com
  • Industry Medical - Devices
  • CEO Paul Badawi
  • Employees 216
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.